

Dominique Costagliola

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7546987/dominique-costagliola-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

524
papers

24,562
citations

78
h-index

138
g-index

556
ext. papers

27,611
ext. citations

6.1
avg, IF

6.42
L-index

#	Paper	IF	Citations
524	A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial.. <i>Lancet HIV,the</i> , 2022 , 9, e79-e90	7.8	4
523	Household transmission of SARS-CoV-2 infection in the Paris/Ile-de-France area.. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2022 , 1	5.3	0
522	Coronary Angiographic Features and Major Adverse Cardiac or Cerebrovascular Events in People Living With Human Immunodeficiency Virus Presenting With Acute Coronary Syndrome.. <i>Circulation: Cardiovascular Interventions</i> , 2022 , 101161CIRCINTERVENTIONS122011945	6	0
521	Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19. <i>Lancet Infectious Diseases, The</i> , 2022 , 22, 764-765	25.5	0
520	Withholding Primary Pneumocystis Pneumonia Prophylaxis in Virologically Suppressed Patients With Human Immunodeficiency Virus: An Emulation of a Pragmatic Trial in COHERE. <i>Clinical Infectious Diseases</i> , 2021 , 73, 195-202	11.6	2
519	Metabolic Syndrome and Cardiovascular Disease Impacts on the Pathophysiology and Phenotype of HIV-Associated Neurocognitive Disorders. <i>Current Topics in Behavioral Neurosciences</i> , 2021 , 50, 367-399	3.4	3
518	Accelerating clinical trial implementation in the context of the COVID-19 pandemic: challenges, lessons learned and recommendations from DisCoVeRy and the EU-SolidAct EU response group. <i>Clinical Microbiology and Infection</i> , 2021 ,	9.5	3
517	Epidemiology of Kaposi's Sarcoma. <i>Cancers</i> , 2021 , 13,	6.6	3
516	A new SARS-CoV-2 variant with high lethality poorly detected by RT-PCR on nasopharyngeal samples: an observational study. <i>Clinical Microbiology and Infection</i> , 2021 ,	9.5	2
515	CD4/CD8 Ratio and the Risk of Kaposi Sarcoma or Non-Hodgkin Lymphoma in the Context of Efficiently Treated Human Immunodeficiency Virus (HIV) Infection: A Collaborative Analysis of 20 European Cohort Studies. <i>Clinical Infectious Diseases</i> , 2021 , 73, 50-59	11.6	6
514	Revealing HIV epidemic dynamics and contrasting responses in two WHO Eastern European countries: insights from modeling and data triangulation. <i>Aids</i> , 2021 , 35, 675-680	3.5	0
513	Genetic variation near CXCL12 is associated with susceptibility to HIV-related non-Hodgkin lymphoma. <i>Haematologica</i> , 2021 , 106, 2233-2241	6.6	1
512	Chronic use of renin-angiotensin-aldosterone system blockers and mortality in COVID-19: A multicenter prospective cohort and literature review. <i>Fundamental and Clinical Pharmacology</i> , 2021 , 35, 1141-1158	3.1	1
511	An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN- α and hydroxychloroquine in hospitalized patients with COVID-19. <i>Clinical Microbiology and Infection</i> , 2021 , 27, 1826-1837	9.5	27
510	COVID-19: individual and herd immunity. <i>Comptes Rendus - Biologies</i> , 2021 , 344, 7-18	1.4	0
509	No need for secondary <i>Pneumocystis jirovecii</i> pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/ μ L. <i>Journal of the International AIDS Society</i> , 2021 , 24, e25726	5.4	2
508	Pharmacological data of a successful 4-days-a-week regimen in HIV antiretroviral therapy (ANRS 162-4D trial). <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 1930-1939	3.8	0

507	Use of rilpivirine in HIV-1-infected individuals in routine clinical practice from 2012 to 2017 in France. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 467-476	5.1	0
506	A Comparison of Cell Activation, Exhaustion, and Expression of HIV Coreceptors and Restriction Factors in HIV-1- and HIV-2-Infected Nonprogressors. <i>AIDS Research and Human Retroviruses</i> , 2021 , 37, 214-223	1.6	1
505	Prospective evaluation of blood Epstein-Barr virus DNA load and antibody profile in HIV-related non-Hodgkin lymphomas. <i>Aids</i> , 2021 , 35, 861-868	3.5	2
504	Can HIV epidemics among MSM be eliminated through participation in preexposure prophylaxis rollouts?. <i>Aids</i> , 2021 , 35, 2347-2354	3.5	0
503	Do people living with HIV face more secondary cancers than general population: From the French CANCERVIH network. <i>Bulletin Du Cancer</i> , 2021 , 108, 908-914	2.4	1
502	Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. <i>Lancet Infectious Diseases</i> , 2021 ,	25.5	66
501	Hepatitis C virus (HCV) incidence among men who have sex with men (MSM) living with HIV: results from the French Hospital Database on HIV (ANRS CO4-FHDH) cohort study, 2014 to 2017. <i>Eurosurveillance</i> , 2021 , 26,	19.8	2
500	How PrEP users constitute a community in the MSM population through their specific experience and management of stigmatization. The example of the French ANRS-PREVENIR study. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2020 , 32, 32-39	2.2	9
499	Cause-specific mortality after diagnosis of cancer among HIV-positive patients: A collaborative analysis of cohort studies. <i>International Journal of Cancer</i> , 2020 , 146, 3134-3146	7.5	6
498	Risk of Severe Bacterial Infection in People Living Human Immunodeficiency Virus Infection in the Combined Antiretroviral Therapy Era. <i>Journal of Infectious Diseases</i> , 2020 , 222, 765-776	7	
497	Characterization of viral rebounds on dual etravirine/raltegravir maintenance therapy (ANRS-163 ETRAL trial). <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 1943-1949	5.1	0
496	Factors Influencing the Incubation of an Infectious Form of Creutzfeldt-Jakob Disease. <i>Clinical Infectious Diseases</i> , 2020 , 70, 1487-1490	11.6	1
495	Risk Factors for Seborrheic Dermatitis Flares: Case-control and Case-crossover Study. <i>Acta Dermato-Venereologica</i> , 2020 , 100, adv00292	2.2	1
494	In situ BCL2 expression is an independent prognostic factor in HIV-associated DLBCL, a LYMPHOVIR cohort study. <i>British Journal of Haematology</i> , 2020 , 188, 413-423	4.5	2
493	Potential lung cancer screening outcomes using different age and smoking thresholds in the ANRS-CO4 French Hospital Database on HIV cohort. <i>HIV Medicine</i> , 2020 , 21, 180-188	2.7	2
492	Hepatitis C virus or hepatitis B virus coinfection and lymphoma risk in people living with HIV. <i>Aids</i> , 2020 , 34, 599-608	3.5	4
491	Is the Risk of Myocardial Infarction in People With Human Immunodeficiency Virus (HIV) Associated With Atazanavir or Darunavir? A Nested Case-Control Study Within the French Hospital Database on HIV. <i>Journal of Infectious Diseases</i> , 2020 , 221, 516-522	7	3
490	Increased Prevalence of Neurocognitive Impairment in Aging People Living With Human Immunodeficiency Virus: The ANRS EP58 HAND 55-70 Study. <i>Clinical Infectious Diseases</i> , 2020 , 70, 2641-2648	11.6	9

489	Re-engagement in care of people living with HIV lost to follow-up after initiation of antiretroviral therapy in Mali: Who returns to care?. <i>PLoS ONE</i> , 2020 , 15, e0238687	3.7	2
488	Favorable outcome of HIV-associated Burkitt lymphoma in the modern combined antiretroviral therapy era. <i>European Journal of Cancer</i> , 2020 , 138, 189-192	7.5	2
487	Human Immunodeficiency Virus Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population: Have We Made Progress?. <i>Clinical Infectious Diseases</i> , 2020 , 71, 2905-2916 ³	11.6	16
486	Addition of Maraviroc Versus Placebo to Standard Antiretroviral Therapy for Initial Treatment of Advanced HIV Infection: A Randomized Trial. <i>Annals of Internal Medicine</i> , 2020 , 172, 297-305	8	4
485	RE: "EARLY OUTPATIENT TREATMENT OF SYMPTOMATIC, HIGH-RISK COVID-19 PATIENTS THAT SHOULD BE RAMPED UP IMMEDIATELY AS KEY TO THE PANDEMIC CRISIS". <i>American Journal of Epidemiology</i> , 2020 , 189, 1443-1444	3.8	5
484	Trajectories of functioning in bipolar disorders: A longitudinal study in the FondaMental Advanced Centers of Expertise in Bipolar Disorders cohort. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020 , 54, 985-996	2.6	3
483	Estimating the burden of HIV late presentation and its attributable morbidity and mortality across Europe 2010-2016. <i>BMC Infectious Diseases</i> , 2020 , 20, 728	4	12
482	HIV Infection and Long-Term Residual Cardiovascular Risk After Acute Coronary Syndrome. <i>Journal of the American Heart Association</i> , 2020 , 9, e017578	6	5
481	Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study-authors' response. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 3699-3700	5.1	1
480	Fat gain differs by sex and hormonal status in persons living with suppressed HIV switched to raltegravir/etravirine. <i>Aids</i> , 2020 , 34, 1859-1862	3.5	5
479	Prevalence of tubulopathy and association with renal function loss in HIV-infected patients. <i>Nephrology Dialysis Transplantation</i> , 2020 , 35, 607-615	4.3	4
478	Propensity Score Analysis of Artesunate Versus Quinine for Severe Imported Plasmodium falciparum Malaria in France. <i>Clinical Infectious Diseases</i> , 2020 , 70, 280-287	11.6	9
477	Recurrence and Occurrence of Kaposi's Sarcoma in Patients Living With Human Immunodeficiency Virus (HIV) and on Antiretroviral Therapy, Despite Suppressed HIV Viremia. <i>Clinical Infectious Diseases</i> , 2020 , 70, 2435-2438	11.6	11
476	Low incidence of acute rejection within 6 months of kidney transplantation in HIV-infected recipients treated with raltegravir: the Agence Nationale de Recherche sur le Sida et les Hpatites Virales (ANRS) 153 TREVE trial. <i>HIV Medicine</i> , 2019 , 20, 202-213	2.7	3
475	Invasive cervical cancer in HIV-infected women: risk and survival relative to those of the general population in France. Results from the French Hospital Database on HIV (FHDH)-Agence Nationale de Recherches sur le SIDA et les Hpatites Virales (ANRS) CO4 cohort study. <i>HIV Medicine</i> , 2019 , 20, 222-229	2.7	7
474	Trends in the risk of myocardial infarction among HIV-1-infected individuals relative to the general population in France: Impact of gender and immune status. <i>PLoS ONE</i> , 2019 , 14, e0210253	3.7	5
473	Are European HIV cohort data within EuroCoord representative of the diagnosed HIV population?. <i>Aids</i> , 2019 , 33, 133-143	3.5	15
472	Effect Estimates in Randomized Trials and Observational Studies: Comparing Apples With Apples. <i>American Journal of Epidemiology</i> , 2019 , 188, 1569-1577	3.8	45

471	Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS-163 ETRAL Study. <i>Pharmacotherapy</i> , 2019 , 39, 514-520	5.8	2
470	Routine screening for HIV, hepatitis B virus and hepatitis C virus in individuals undergoing oral and maxillofacial surgery. <i>HIV Medicine</i> , 2019 , 20, 353-358	2.7	0
469	Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV-positive individuals. <i>Statistics in Medicine</i> , 2019 , 38, 2428-2446	2.3	10
468	Impact of Antiretroviral Drugs on Fracture Risk in HIV-Infected Individuals: A Case-Control Study Nested Within the French Hospital Database on HIV (FHDH-ANRS CO4). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019 , 80, 214-223	3.1	6
467	Use of darunavir in HIV-1-infected individuals in routine clinical practice from 2012 to 2016 in France. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 3305-3314	5.1	5
466	Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients. <i>Open Forum Infectious Diseases</i> , 2019 , 6, ofz330	1	16
465	Access to the waiting list and to kidney transplantation for people living with HIV: A national registry study. <i>American Journal of Transplantation</i> , 2019 , 19, 3345-3355	8.7	11
464	Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 2742-2751	5.1	17
463	Estimates of the HIV undiagnosed population in Belgium reveals higher prevalence for MSM with foreign nationality and for geographic areas hosting big cities. <i>Journal of the International AIDS Society</i> , 2019 , 22, e25371	5.4	7
462	Epstein-Barr virus biomarkers have no prognostic value in HIV-related Hodgkin lymphoma in the modern combined antiretroviral therapy era. <i>Aids</i> , 2019 , 33, 993-1000	3.5	5
461	Brief Report: Impact of ART Classes on the Increasing Risk of Cerebral Small-Vessel Disease in Middle-Aged, Well-Controlled, cART-Treated, HIV-Infected Individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019 , 81, 547-551	3.1	5
460	Determinants of Restoration of CD4 and CD8 Cell Counts and Their Ratio in HIV-1-Positive Individuals With Sustained Virological Suppression on Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019 , 80, 292-300	3.1	6
459	Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019 , 80, e86-e94	3.1	26
458	Utility of Epstein-Barr Virus Biomarkers in Human Immunodeficiency Virus-related Lymphomas in the Modern Combined Antiretroviral Therapy Era. <i>Clinical Infectious Diseases</i> , 2019 , 68, 891-892	11.6	4
457	Validation and refinement of the clinical staging model in a French cohort of outpatient with schizophrenia (FACE-SZ). <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019 , 92, 226-234	5.5	8
456	Risk factors for loss to follow-up, transfer or death among people living with HIV on their first antiretroviral therapy regimen in Mali. <i>HIV Medicine</i> , 2019 , 20, 47-53	2.7	5
455	Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs. <i>Clinical Infectious Diseases</i> , 2018 , 66, 893-903	11.6	75
454	Four-days-a-week antiretroviral maintenance therapy in virologically controlled HIV-1-infected adults: the ANRS 162-4D trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 738-747	5.1	15

453	Revealing geographical and population heterogeneity in HIV incidence, undiagnosed HIV prevalence and time to diagnosis to improve prevention and care: estimates for France. <i>Journal of the International AIDS Society</i> , 2018 , 21, e25100	5.4	32
452	Risk of Progressive Multifocal Leukoencephalopathy in the Combination Antiretroviral Therapy Era in the French Hospital Database on Human Immunodeficiency Virus (ANRS-C4). <i>Clinical Infectious Diseases</i> , 2018 , 67, 275-282	11.6	8
451	Silent Cerebral Small-Vessel Disease Is Twice as Prevalent in Middle-Aged Individuals With Well-Controlled, Combination Antiretroviral Therapy-Treated Human Immunodeficiency Virus (HIV) Than in HIV-Uninfected Individuals. <i>Clinical Infectious Diseases</i> , 2018 , 66, 1762-1769	11.6	29
450	Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018 , 77, 102-109	3.1	2
449	Susceptibility to Creutzfeldt-Jakob disease after human growth hormone treatment in France. <i>Neurology</i> , 2018 , 91, e724-e731	6.5	3
448	Impact of etravirine on hospitalization rate between 2005 and 2011 among heavily treated HIV-1-infected individuals on failing regimens. <i>BMC Infectious Diseases</i> , 2018 , 18, 326	4	1
447	Long terms trends in CD4+ cell counts, CD8+ cell counts, and the CD4+ : CD8+ ratio. <i>Aids</i> , 2018 , 32, 1361-1367	13.67	12
446	Metabolic Syndrome and Illness Severity Predict Relapse at 1-Year Follow-Up in Schizophrenia: The FACE-SZ Cohort. <i>Journal of Clinical Psychiatry</i> , 2018 , 79,	4.6	17
445	Targeted HIV Screening in Eight Emergency Departments: The DICI-VIH Cluster-Randomized Two-Period Crossover Trial. <i>Annals of Emergency Medicine</i> , 2018 , 72, 41-53.e9	2.1	11
444	Influence of geographic origin on AIDS and serious non-AIDS morbidity/mortality during cART among heterosexual HIV-infected men and women in France. <i>PLoS ONE</i> , 2018 , 13, e0205385	3.7	1
443	CD4+ cell count recovery after combined antiretroviral therapy in the modern combined antiretroviral therapy era. <i>Aids</i> , 2018 , 32, 2605-2614	3.5	19
442	Lack of effects of statins on high-density lipoprotein subfractions in HIV-1-infected patients receiving protease inhibitors. <i>Comptes Rendus - Biologies</i> , 2017 , 340, 109-113	1.4	4
441	Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study. <i>Lancet HIV</i> , 2017 , 4, e251-e259	7.8	9
440	CD4+/CD8+ ratio restoration in long-term treated HIV-1-infected individuals. <i>Aids</i> , 2017 , 31, 1685-1695	3.5	15
439	Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study. <i>Clinical Infectious Diseases</i> , 2017 , 65, 1316-1326	11.6	23
438	The Human Immunodeficiency Virus Continuum of Care in European Union Countries in 2013: Data and Challenges. <i>Clinical Infectious Diseases</i> , 2017 , 64, 1644-1656	11.6	42
437	Performance of the marginal structural cox model for estimating individual and joined effects of treatments given in combination. <i>BMC Medical Research Methodology</i> , 2017 , 17, 160	4.7	8
436	CD4 T cell decline following HIV seroconversion in individuals with and without CXCR4-tropic virus. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 2862-2868	5.1	4

435	Cohort Profile: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. <i>International Journal of Epidemiology</i> , 2017 , 46, 797-797n	7.8	17
434	Sleep quality, chronotype and metabolic syndrome components in bipolar disorders during the remission period: Results from the FACE-BD cohort. <i>Chronobiology International</i> , 2017 , 34, 1114-1124	3.6	12
433	Outcomes for bipolar patients assessed in the French expert center network: A 2-year follow-up observational study (FondaMental Advanced Centers of Expertise for Bipolar Disorder [FACE-BD]). <i>Bipolar Disorders</i> , 2017 , 19, 651-660	3.8	13
432	Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era. <i>Aids</i> , 2017 , 31, 2493-2501	3.5	33
431	Effect of Immediate Initiation of Antiretroviral Treatment in HIV-Positive Individuals Aged 50 Years or Older. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017 , 76, 311-318	3.1	8
430	Predictors of rapid high weight gain in schizophrenia: Longitudinal analysis of the French FACE-SZ cohort. <i>Journal of Psychiatric Research</i> , 2017 , 94, 62-69	5.2	10
429	CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus-Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC). <i>Clinical Infectious Diseases</i> , 2017 , 65, 959-966	11.6	50
428	Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in Europe. <i>HIV Medicine</i> , 2017 , 18, 171-180	2.7	33
427	Statin therapy and low-density lipoprotein cholesterol reduction in HIV-infected individuals after acute coronary syndrome: Results from the PACS-HIV lipids substudy. <i>American Heart Journal</i> , 2017 , 183, 91-101	4.9	18
426	Phase II Trial of Lenalidomide in HIV-Infected Patients with Previously Treated Kaposi's Sarcoma: Results of the ANRS 154 Lenakap Trial. <i>AIDS Research and Human Retroviruses</i> , 2017 , 33, 1-10	1.6	20
425	Risk of HIV transmission during combined ART initiation for HIV-infected persons with severe immunosuppression. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 3172-3176	5.1	4
424	CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 2869-2878	5.1	11
423	Loss of long-term non-progressor and HIV controller status over time in the French Hospital Database on HIV - ANRS CO4. <i>PLoS ONE</i> , 2017 , 12, e0184441	3.7	11
422	Switching to Raltegravir From a Virologically Effective Boosted Protease Inhibitor Regimen: A Comparative Effectiveness Analysis From the French Hospital Database on HIV (FHDH-ANRS CO4). <i>Clinical Infectious Diseases</i> , 2016 , 63, 1254-1261	11.6	5
421	Looking Beyond the Cascade of HIV Care to End the AIDS Epidemic: Estimation of the Time Interval From HIV Infection to Viral Suppression. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016 , 73, 348-355	3.1	33
420	Survival in individuals living with HIV. <i>Current Opinion in HIV and AIDS</i> , 2016 , 11, 451-454	4.2	2
419	Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: A prospective study of HIV-positive individuals. <i>Medicine (United States)</i> , 2016 , 95, e5133	1.8	2
418	Influence of geographic origin, sex, and HIV transmission group on the outcome of first-line combined antiretroviral therapy in France. <i>Aids</i> , 2016 , 30, 2235-46	3.5	8

417	Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNA: a randomized trial. <i>Aids</i> , 2016 , 30, 221-30	3.5	43
416	Cancers in elite controllers: appropriate follow-up is essential. <i>Aids</i> , 2016 , 30, 1852-5	3.5	4
415	Prevalence of and Risk Factors for Anal Oncogenic Human Papillomavirus Infection Among HIV-Infected Women in France in the Combination Antiretroviral Therapy Era. <i>Journal of Infectious Diseases</i> , 2016 , 213, 1455-61	7	24
414	Determinants of a Low CD4/CD8 Ratio in HIV-1-Infected Individuals Despite Long-term Viral Suppression. <i>Clinical Infectious Diseases</i> , 2016 , 62, 1297-1303	11.6	44
413	Non-AIDS-related malignancies: expert consensus review and practical applications from the multidisciplinary CANCEVIH Working Group. <i>Annals of Oncology</i> , 2016 , 27, 397-408	10.3	31
412	Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy. <i>International Journal of Epidemiology</i> , 2016 , 45, 2038-2049	7.8	24
411	Immunity, inflammation and reservoir in patients at an early stage of HIV infection on intermittent ART (ANRS 141 TIPI Trial). <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 490-6	5.1	1
410	The impact of nurse-driven targeted HIV screening in 8 emergency departments: study protocol for the DICI-VIH cluster-randomized two-period crossover trial. <i>BMC Infectious Diseases</i> , 2016 , 16, 51	4	4
409	The impact of transient combination antiretroviral treatment in early HIV infection on viral suppression and immunologic response in later treatment. <i>Aids</i> , 2016 , 30, 879-88	3.5	8
408	Residual immune activation in combined antiretroviral therapy-treated patients with maximally suppressed viremia. <i>Aids</i> , 2016 , 30, 327-30	3.5	23
407	Treatment interruption in chronically HIV-infected patients with an ultralow HIV reservoir. <i>Aids</i> , 2016 , 30, 761-9	3.5	54
406	Rosuvastatin Is Effective to Decrease CD8 T-Cell Activation Only in HIV-Infected Patients With High Residual T-Cell Activation Under Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016 , 71, 390-8	3.1	10
405	When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries: A Prospective Observational Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016 , 72, 214-21	3.1	11
404	Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study. <i>Clinical Infectious Diseases</i> , 2016 , 62, 1571-1577	11.6	40
403	Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial). <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 2252-61	5.1	6
402	Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor-based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized Trials. <i>Clinical Infectious Diseases</i> , 2016 , 63, 268-80	11.6	11
401	Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. <i>Clinical Infectious Diseases</i> , 2016 , 63, 1245-1253	11.6	15
400	HIV-1-RNA in seminal plasma correlates with detection of HIV-1-DNA in semen cells, but not with CMV shedding, among MSM on successful antiretroviral regimens. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 3202-3205	5.1	11

399	Time for a revolution in tracking the HIV epidemic. <i>Lancet HIV,the</i> , 2016 , 3, e337-e339	7.8	6
398	Effect of therapeutic intensification followed by HIV DNA prime and rAd5 boost vaccination on HIV-specific immunity and HIV reservoir (EraMune 02): a multicentre randomised clinical trial. <i>Lancet HIV,the</i> , 2015 , 2, e82-91	7.8	27
397	Relevance of EORTC Criteria for the Diagnosis of Invasive Aspergillosis in HIV-Infected Patients, and Survival Trends Over a 20-Year Period in France. <i>Clinical Infectious Diseases</i> , 2015 , 61, 1273-80	11.6	18
396	Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study. <i>Lancet HIV,the</i> , 2015 , 2, e335-43	7.8	41
395	High Prevalence of Anal Human Papillomavirus-Associated Cancer Precursors in a Contemporary Cohort of Asymptomatic HIV-Infected Women. <i>Clinical Infectious Diseases</i> , 2015 , 60, 1559-68	11.6	26
394	GBD 2013 and HIV incidence in high income countries. <i>Lancet, The</i> , 2015 , 385, 1177	4.0	6
393	Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America. <i>Aids</i> , 2015 , 29, 221-9	3.5	168
392	Obesity in HIV-infected patients in France: prevalence and surgical treatment options. <i>Journal of Visceral Surgery</i> , 2015 , 152, 33-7	1.9	11
391	Virological factors associated with outcome of dual maraviroc/raltegravir therapy (ANRS-157 trial). <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 3339-44	5.1	6
390	Impact of migration origin on individual protection strategies against sexual transmission of HIV in Paris metropolitan area, SIRS cohort study, France. <i>BMC Public Health</i> , 2015 , 15, 807	4.1	2
389	High Risk Features Contrast With Favorable Outcomes in HIV-associated Hodgkin Lymphoma in the Modern cART Era, ANRS CO16 LYMPHOVIR Cohort. <i>Clinical Infectious Diseases</i> , 2015 , 61, 1469-75	11.6	34
388	Burden of HIV and hepatitis C co-infection: the changing epidemiology of hepatitis C in HIV-infected patients in France. <i>Liver International</i> , 2015 , 35, 65-70	7.9	24
387	Which adults in the Paris metropolitan area have never been tested for HIV? A 2010 multilevel, cross-sectional, population-based study. <i>BMC Infectious Diseases</i> , 2015 , 15, 278	4	5
386	Antiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 566-72	5.1	7
385	Is statin preventing cancer in HIV-1 infected individuals? An inappropriate methodology is a more likely explanation. <i>Aids</i> , 2015 , 29, 857	3.5	
384	Switch to maraviroc/raltegravir dual therapy leads to an unfavorable immune profile with low-level HIV viremia. <i>Aids</i> , 2015 , 29, 853-6	3.5	5
383	A low HIV-DNA level in peripheral blood mononuclear cells at antiretroviral treatment interruption predicts a higher probability of maintaining viral control. <i>Aids</i> , 2015 , 29, 2003-7	3.5	50
382	Risk of HIV transmission under combined antiretroviral therapy: toward risk zero?. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015 , 68, e41-2	3.1	2

381	Interobserver variability of cervical cytology in HIV-infected women. <i>Cytopathology</i> , 2015 , 26, 362-7	1.3	2
380	Soluble biomarkers of immune activation and inflammation in HIV infection: impact of 2 years of effective first-line combination antiretroviral therapy. <i>HIV Medicine</i> , 2015 , 16, 553-62	2.7	38
379	Trends in survival after cancer diagnosis among HIV-infected individuals between 1992 and 2009. Results from the FHDH-ANRS CO4 cohort. <i>International Journal of Cancer</i> , 2015 , 137, 2443-53	7.5	36
378	Later cART initiation in migrant men from sub-Saharan Africa without advanced HIV disease in France. <i>PLoS ONE</i> , 2015 , 10, e0118492	3.7	9
377	Is Impact of Statin Therapy on All-Cause Mortality Different in HIV-Infected Individuals Compared to General Population? Results from the FHDH-ANRS CO4 Cohort. <i>PLoS ONE</i> , 2015 , 10, e0133358	3.7	13
376	Durability and Effectiveness of Maraviroc-Containing Regimens in HIV-1-Infected Individuals with Virological Failure in Routine Clinical Practice. <i>PLoS ONE</i> , 2015 , 10, e0144746	3.7	1
375	A multifaceted intervention designed to improve medical management of moderate to advanced chronic kidney disease in HIV-infected patients: a cluster randomized trial. <i>Clinical Infectious Diseases</i> , 2015 , 61, 375-84	11.6	1
374	Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions. <i>Neurology</i> , 2015 , 84, 632	6.5	1
373	Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4+ T-cell recovery once HIV-1 suppression is achieved?. <i>Aids</i> , 2015 , 29, 2323-33	3.5	14
372	Tackling latency as a barrier to an HIV cure: what next?. <i>Lancet HIV, the</i> , 2015 , 2, e504-5	7.8	0
371	Liver-related deaths in HIV-infected patients between 1995 and 2010 in France: the Mortavic 2010 study in collaboration with the Agence Nationale de Recherche sur le SIDA (ANRS) EN 20 Mortalit ^e 2010 survey. <i>HIV Medicine</i> , 2015 , 16, 230-9	2.7	54
370	Incidence of herpes zoster in HIV-infected adults in the combined antiretroviral therapy era: results from the FHDH-ANRS CO4 cohort. <i>Clinical Infectious Diseases</i> , 2015 , 60, 1269-77	11.6	33
369	Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries. <i>Clinical Infectious Diseases</i> , 2015 , 60, 1262-8	11.6	5
368	Significant reduction in HIV virologic failure during a 15-year period in a setting with free healthcare access. <i>Clinical Infectious Diseases</i> , 2015 , 60, 463-72	11.6	26
367	Cancer-Related Causes of Death among HIV-Infected Patients in France in 2010: Evolution since 2000. <i>PLoS ONE</i> , 2015 , 10, e0129550	3.7	56
366	New indicators for delay in initiation of antiretroviral treatment: estimates for Cameroon. <i>Bulletin of the World Health Organization</i> , 2015 , 93, 521-8	8.2	9
365	Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013. <i>Eurosurveillance</i> , 2015 , 20,	19.8	55
364	HIV-1 DNA levels in peripheral blood mononuclear cells and cannabis use are associated with intermittent HIV shedding in semen of men who have sex with men on successful antiretroviral regimens. <i>Clinical Infectious Diseases</i> , 2014 , 58, 1763-70	11.6	36

363	Temporal trends in prognostic markers of HIV-1 virulence and transmissibility: an observational cohort study. <i>Lancet HIV,the</i> , 2014 , 1, e119-26	7.8	24
362	Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery. <i>Clinical Infectious Diseases</i> , 2014 , 58, 1312-21	11.6	107
361	Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study. <i>BMC Infectious Diseases</i> , 2014 , 14, 122	4	45
360	Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions. <i>Neurology</i> , 2014 , 83, 134-41	6.5	85
359	Blunted response to combination antiretroviral therapy in HIV elite controllers: an international HIV controller collaboration. <i>PLoS ONE</i> , 2014 , 9, e85516	3.7	23
358	Lopinavir/r no longer recommended as a first-line regimen: a comparative effectiveness analysis. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19070	5.4	4
357	CD4+ cell count recovery in naïve patients initiating cART, who achieved and maintained plasma HIV-RNA suppression. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19481	5.4	10
356	Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014 , 65, e8-16	3.1	122
355	Rapid plasma viral suppression in naive HIV-infected patients with high CD4 cells and low viraemia initiating a dual nucleoside reverse transcriptase inhibitor strategy: a proof-of-concept study. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 3356-9	5.1	1
354	Heterosexual risk of HIV transmission per sexual act under combined antiretroviral therapy: systematic review and bayesian modeling. <i>Clinical Infectious Diseases</i> , 2014 , 59, 115-22	11.6	29
353	Mortality in patients with HIV-1 infection starting antiretroviral therapy in South Africa, Europe, or North America: a collaborative analysis of prospective studies. <i>PLoS Medicine</i> , 2014 , 11, e1001718	11.6	89
352	Characteristics of B-cell lymphomas in HIV/HCV-coinfected patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014 , 67, e86-7	3.1	1
351	Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC). <i>International Journal of Epidemiology</i> , 2014 , 43, 691-702	7.8	52
350	Vitamin D supplementation is associated with reduced immune activation levels in HIV-1-infected patients on suppressive antiretroviral therapy. <i>Aids</i> , 2014 , 28, 2677-82	3.5	28
349	T-cell activation positively correlates with cell-associated HIV-DNA level in viremic patients with primary or chronic HIV-1 infection. <i>Aids</i> , 2014 , 28, 1683-7	3.5	16
348	Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000. <i>Aids</i> , 2014 , 28, 1181-91	3.5	170
347	Risk of non-AIDS-defining cancers among HIV-1-infected individuals in France between 1997 and 2009: results from a French cohort. <i>Aids</i> , 2014 , 28, 2109-18	3.5	64
346	Demographics of HIV and aging. <i>Current Opinion in HIV and AIDS</i> , 2014 , 9, 294-301	4.2	65

345	The undiagnosed HIV epidemic in France and its implications for HIV screening strategies. <i>Aids</i> , 2014 , 28, 1797-804	3.5	64
344	Cohort Profile: French hospital database on HIV (FHDH-ANRS CO4). <i>International Journal of Epidemiology</i> , 2014 , 43, 1425-36	7.8	57
343	Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 1648-52	5.1	26
342	Factors associated with short-term changes in HIV viral load and CD4(+) cell count in antiretroviral-naïve individuals. <i>Aids</i> , 2014 , 28, 1351-6	3.5	27
341	Is impaired kidney function an independent predictor of the risk of myocardial infarction in HIV-infected individuals?. <i>Aids</i> , 2014 , 28, 1987-9	3.5	
340	Critical importance of long-term adherence to care in HIV infected patients in the cART era: new insights from <i>Pneumocystis jirovecii</i> pneumonia cases over 2004-2011 in the FHDH-ANRS CO4 cohort. <i>PLoS ONE</i> , 2014 , 9, e94183	3.7	5
339	Metabolic syndrome in a French cohort of patients with bipolar disorder: results from the FACE-BD cohort. <i>Journal of Clinical Psychiatry</i> , 2014 , 75, 1078-85; quiz 1085	4.6	26
338	Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009. <i>Aids</i> , 2013 , 27, 803-13	3.5	65
337	HIV and coronary heart disease: time for a better understanding. <i>Journal of the American College of Cardiology</i> , 2013 , 61, 511-23	15.1	194
336	Risk of Kaposi sarcoma during the first months on combination antiretroviral therapy. <i>Aids</i> , 2013 , 27, 635-43	3.5	14
335	Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. <i>PLoS Pathogens</i> , 2013 , 9, e1003211	7.6	681
334	Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). <i>PLoS Medicine</i> , 2013 , 10, e1001510	11.6	212
333	Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes. <i>Journal of Infectious Diseases</i> , 2013 , 207, 759-67	7	6
332	Risk of AIDS-defining cancers among HIV-1-infected patients in France between 1992 and 2009: results from the FHDH-ANRS CO4 cohort. <i>Clinical Infectious Diseases</i> , 2013 , 57, 1638-47	11.6	72
331	The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/ μ l in the post-combination antiretroviral therapy era. <i>Clinical Infectious Diseases</i> , 2013 , 57, 1038-47	11.6	79
330	β -Blocker use for patients with or at risk for coronary artery disease. <i>JAMA - Journal of the American Medical Association</i> , 2013 , 309, 439	27.4	0
329	Impact of HIV-1 subtype on CD4 count at HIV seroconversion, rate of decline, and viral load set point in European seroconverter cohorts. <i>Clinical Infectious Diseases</i> , 2013 , 56, 888-97	11.6	76
328	Factors associated with late antiretroviral therapy initiation in Cameroon: a representative multilevel analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 1388-99	5.1	21

327	National sentinel surveillance of transmitted drug resistance in antiretroviral-naïve chronically HIV-infected patients in France over a decade: 2001-2011. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 2626-31	5.1	39
326	Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL in 2009: a French nationwide study. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 1400-5	5.1	16
325	Changes in bone mineral density over a 2-year period in HIV-1-infected men under combined antiretroviral therapy with osteopenia. <i>Aids</i> , 2013 , 27, 2425-30	3.5	36
324	Characteristics of B-cell lymphomas in HIV/HCV-coinfected patients during the combined antiretroviral therapy era: an ANRS CO16 LYMPHOVIR cohort study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013 , 63, 249-53	3.1	11
323	Lack of regression of anal squamous intraepithelial lesions despite immune restoration under cART. <i>Aids</i> , 2013 , 27, 401-6	3.5	17
322	MHC-driven HIV-1 control on the long run is not systematically determined at early times post-HIV-1 infection. <i>Aids</i> , 2013 , 27, 1707-16	3.5	13
321	Impact of late presentation on the risk of death among HIV-infected people in France (2003-2009). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013 , 64, 197-203	3.1	48
320	Bleeding complications in primary percutaneous coronary intervention of ST-elevation myocardial infarction in a radial center. <i>Catheterization and Cardiovascular Interventions</i> , 2012 , 79, 104-12	2.7	19
319	Boosted protease inhibitor monotherapy as a maintenance strategy: an observational study. <i>Aids</i> , 2012 , 26, 2345-50	3.5	21
318	Performance of Quantiferon(®) for the diagnosis TB. <i>Médecine Et Maladies Infectieuses</i> , 2012 , 42, 579-84	4	1
317	Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. <i>Lancet Infectious Diseases</i> , 2012 , 12, 119-27	25.5	33
316	NYVAC immunization induces polyfunctional HIV-specific T-cell responses in chronically-infected, ART-treated HIV patients. <i>European Journal of Immunology</i> , 2012 , 42, 3038-48	6.1	29
315	Impact of lopinavir/ritonavir use on antiretroviral resistance in recent clinical practice. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 2487-93	5.1	4
314	Breast cancer among HIV infected individuals from the ONCOVIH study, in France: therapeutic implications. <i>European Journal of Cancer</i> , 2012 , 48, 3335-41	7.5	16
313	Prevalence of low bone mineral density in men and women infected with human immunodeficiency virus 1 and a proposal for screening strategy. <i>Journal of Clinical Densitometry</i> , 2012 , 15, 422-433	3.5	19
312	Twelve months of routine HIV screening in 6 emergency departments in the Paris area: results from the ANRS URDEP study. <i>PLoS ONE</i> , 2012 , 7, e46437	3.7	22
311	Effect of early syphilis infection on plasma viral load and CD4 cell count in human immunodeficiency virus-infected men: results from the FHDH-ANRS CO4 cohort. <i>Archives of Internal Medicine</i> , 2012 , 172, 1237-43		60
310	HIV replication and immune status are independent predictors of the risk of myocardial infarction in HIV-infected individuals. <i>Clinical Infectious Diseases</i> , 2012 , 55, 600-7	11.6	113

309	Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. <i>International Journal of Epidemiology</i> , 2012 , 41, 1807-20	7.8	31
308	Adverse outcome analyses of observational data: assessing cardiovascular risk in HIV disease. <i>Clinical Infectious Diseases</i> , 2012 , 54, 408-13	11.6	15
307	Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries. <i>Clinical Infectious Diseases</i> , 2012 , 54, 1364-72	11.6	53
306	Single-nucleotide polymorphism-defined class I and class III major histocompatibility complex genetic subregions contribute to natural long-term nonprogression in HIV infection. <i>Journal of Infectious Diseases</i> , 2012 , 205, 718-24	7	23
305	Effect of alendronate on HIV-associated osteoporosis: a randomized, double-blind, placebo-controlled, 96-week trial (ANRS 120). <i>AIDS Research and Human Retroviruses</i> , 2012 , 28, 972-80	1.6	36
304	Incidence of HIV-related anal cancer remains increased despite long-term combined antiretroviral treatment: results from the french hospital database on HIV. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4360-6	2.2	115
303	Effects of rosuvastatin versus pravastatin on low-density lipoprotein diameter in HIV-1-infected patients receiving ritonavir-boosted protease inhibitor. <i>Aids</i> , 2012 , 26, 1801-5	3.5	6
302	Undiagnosed HIV prevalence in France: no evidence against universal HIV screening. <i>Aids</i> , 2012 , 26, 2419; author reply 2419-21	3.5	1
301	Determinants of low-density lipoprotein particle diameter during antiretroviral therapy including protease inhibitors in HIV-1-infected patients. <i>Antiviral Therapy</i> , 2012 , 17, 855-60	1.6	5
300	The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study. <i>Aids</i> , 2012 , 26, 1691-705	3.5	28
299	Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012 , 59, 294-9	3.1	12
298	HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis. <i>Blood</i> , 2011 , 117, 5142-51	2.2	113
297	Risk of triple-class virological failure in children with HIV: a retrospective cohort study. <i>Lancet, The</i> , 2011 , 377, 1580-7	4.0	87
296	Improved survival of HIV-1-infected patients with progressive multifocal leukoencephalopathy receiving early 5-drug combination antiretroviral therapy. <i>PLoS ONE</i> , 2011 , 6, e20967	3.7	42
295	New method for estimating HIV incidence and time from infection to diagnosis using HIV surveillance data: results for France. <i>Aids</i> , 2011 , 25, 1905-13	3.5	41
294	Alpha interferon administration during structured interruptions of combination antiretroviral therapy in patients with chronic HIV-1 infection: INTERVAC ANRS 105 trial. <i>Aids</i> , 2011 , 25, 115-8	3.5	26
293	Old age and anti-cytomegalovirus immunity are associated with altered T-cell reconstitution in HIV-1-infected patients. <i>Aids</i> , 2011 , 25, 1813-22	3.5	121
292	Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine. <i>Aids</i> , 2011 , 25, 27-36	3.5	37

291	HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy. <i>Blood</i> , 2011 , 118, 44-9	2.2	56
290	When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. <i>Annals of Internal Medicine</i> , 2011 , 154, 509-15	8	167
289	Late presentation of HIV infection: a consensus definition. <i>HIV Medicine</i> , 2011 , 12, 61-4	2.7	279
288	The spectrum of malignancies in HIV-infected patients in 2006 in France: the ONCOVIH study. <i>International Journal of Cancer</i> , 2011 , 129, 467-75	7.5	60
287	Heparin or enoxaparin anticoagulation for primary percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2011 , 77, 182-90	2.7	26
286	Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 1869-77	5.1	6
285	Survival after neuroAIDS: association with antiretroviral CNS Penetration-Effectiveness score. <i>Neurology</i> , 2011 , 76, 644-51	6.5	33
284	High-sensitivity C-reactive protein levels fall during statin therapy in HIV-infected patients receiving ritonavir-boosted protease inhibitors. <i>Aids</i> , 2011 , 25, 1128-31	3.5	31
283	Acute coronary syndrome in human immunodeficiency virus-infected patients: characteristics and 1 year prognosis. <i>European Heart Journal</i> , 2011 , 32, 41-50	9.5	76
282	A therapeutic dendritic cell-based vaccine for HIV-1 infection. <i>Journal of Infectious Diseases</i> , 2011 , 203, 473-8	7	89
281	Preferential amplification of CD8 effector-T cells after transcutaneous application of an inactivated influenza vaccine: a randomized phase I trial. <i>PLoS ONE</i> , 2010 , 5, e10818	3.7	75
280	Relationship between regulatory T cells and immune activation in human immunodeficiency virus-infected patients interrupting antiretroviral therapy. <i>PLoS ONE</i> , 2010 , 5, e11659	3.7	41
279	Routine HIV screening in France: clinical impact and cost-effectiveness. <i>PLoS ONE</i> , 2010 , 5, e13132	3.7	72
278	Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. <i>Archives of Internal Medicine</i> , 2010 , 170, 1228-38		227
277	Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naïve chronically HIV-infected patients from 2001 to 2006/2007 in France. <i>Journal of Antimicrobial Chemotherapy</i> , 2010 , 65, 2620-7	5.1	59
276	Does enfuvirtide increase the risk of bacterial pneumonia in patients receiving combination antiretroviral therapy?. <i>Journal of Antimicrobial Chemotherapy</i> , 2010 , 65, 138-44	5.1	3
275	Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. <i>Clinical Infectious Diseases</i> , 2010 , 50, 1387-96	11.6	448
274	Causes of death in HIV-infected women: persistent role of AIDS. The 'Mortalit'2000 & 2005' Surveys (ANRS EN19). <i>International Journal of Epidemiology</i> , 2010 , 39, 135-46	7.8	20

273	IL-2 therapy: potential impact of the CD4 cell count at initiation on clinical efficacy--results from the ANRS CO4 cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2010 , 65, 2215-23	5.1	7
272	Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2010 , 65, 556-61	5.1	23
271	Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 728-33	5.9	42
270	Relative contributions of baseline patient characteristics and the choice of statistical methods to the variability of genotypic resistance scores: the example of didanosine. <i>Journal of Antimicrobial Chemotherapy</i> , 2010 , 65, 752-60	5.1	5
269	Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion. <i>Journal of the National Cancer Institute</i> , 2010 , 102, 784-92	9.7	92
268	Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. <i>Aids</i> , 2010 , 24, 1228-30	3.5	221
267	Enoxaparin anticoagulation monitoring in the catheterization laboratory using a new bedside test. <i>Journal of the American College of Cardiology</i> , 2010 , 55, 617-25	15.1	20
266	Early initiation of treatment for HIV infection. <i>Lancet, The</i> , 2010 , 375, 639	4.0	4
265	Better health-related quality of life after switching from a virologically effective regimen to a regimen containing efavirenz or nevirapine. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2010 , 22, 54-61	2.2	13
264	The cost of managing HIV infection in highly treatment-experienced, HIV-infected adults in France. <i>Pharmacoeconomics</i> , 2010 , 28 Suppl 1, 59-68	4.4	6
263	Modelling the budget impact of darunavir in the treatment of highly treatment-experienced, HIV-infected adults in France. <i>Pharmacoeconomics</i> , 2010 , 28 Suppl 1, 183-97	4.4	6
262	The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. <i>Aids</i> , 2010 , 24, 123-37	3.5	270
261	Immune and virological benefits of 10 years of permanent viral control with antiretroviral therapy. <i>Aids</i> , 2010 , 24, 614-7	3.5	40
260	Development of a didanosine genotypic resistance interpretation system based on large derivation and validation datasets. <i>Aids</i> , 2010 , 24, 365-71	3.5	5
259	Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years. <i>Archives of Internal Medicine</i> , 2010 , 170, 410-9		35
258	A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipotrophy. <i>HIV Clinical Trials</i> , 2010 , 11, 39-50		26
257	Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial. <i>Aids</i> , 2010 , 24, 77-83	3.5	61
256	HIV-associated tuberculosis and immigration in a high-income country: incidence trends and risk factors in recent years. <i>Aids</i> , 2010 , 24, 763-71	3.5	20

255	When to start treatment? A systematic approach to the comparison of dynamic regimes using observational data. <i>International Journal of Biostatistics</i> , 2010 , 6, Article 18	1.3	115
254	Abacavir and cardiovascular risk: reviewing the evidence. <i>Current HIV/AIDS Reports</i> , 2010 , 7, 127-33	5.9	32
253	Skin cancers associated with HIV infection and solid-organ transplantation among elderly adults. <i>International Journal of Cancer</i> , 2010 , 126, 1724-31	7.5	78
252	A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir. <i>Journal of Medical Virology</i> , 2010 , 82, 1819-28	19.7	37
251	Distinct differentiation profiles of HIV-Gag and Nef-specific central memory CD8+ T cells associated with HLA-B57/5801 and virus control. <i>Aids</i> , 2010 , 24, 2323-9	3.5	15
250	Low prevalence of HIV type 1 drug resistance mutations in untreated, recently infected patients from Burkina Faso, Cte d'Ivoire, Senegal, Thailand, and Vietnam: the ANRS 12134 study. <i>AIDS Research and Human Retroviruses</i> , 2009 , 25, 1193-6	1.6	36
249	Hepatitis B vaccine and the risk of CNS inflammatory demyelination in childhood. <i>Neurology</i> , 2009 , 73, 1426-7	6.5	3
248	Interleukine-2 therapy does not increase the risk of Hodgkin or non-Hodgkin lymphoma in HIV-infected patients: results from FHDH ANRS CO4. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009 , 50, 206-14	3.1	8
247	Impact of HIV infection on severity of imported malaria is restricted to patients with CD4 cell counts <i>Aids</i> , 2009 , 23, 1997-2004	3.5	21
246	Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial. <i>Aids</i> , 2009 , 23, 1605-8	3.5	10
245	A step ahead on the HIV collaboratory. <i>Science</i> , 2009 , 324, 1264-5	33.3	4
244	Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. <i>International Journal of Epidemiology</i> , 2009 , 38, 1624-33	7.8	158
243	Observation plans in longitudinal studies with time-varying treatments. <i>Statistical Methods in Medical Research</i> , 2009 , 18, 27-52	2.3	61
242	Changes in cancer mortality among HIV-infected patients: the Mortalit ² 2005 Survey. <i>Clinical Infectious Diseases</i> , 2009 , 48, 633-9	11.6	121
241	Anticardiolipin antibodies in HIV infection are independently associated with antibodies to the membrane proximal external region of gp41 and with cell-associated HIV DNA and immune activation. <i>Clinical Infectious Diseases</i> , 2009 , 48, 123-32	11.6	45
240	How does loss to follow-up influence cohort findings on HIV infection? A joint analysis of the French hospital database on HIV, Mortalit ² 2000 survey and death certificates. <i>HIV Medicine</i> , 2009 , 10, 236-45	2.7	23
239	Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 study in collaboration with the Mortalit ² 2005 survey, ANRS EN19). <i>HIV Medicine</i> , 2009 , 10, 282-9	2.7	82
238	Drug interactions between antineoplastic and antiretroviral therapies: Implications and management for clinical practice. <i>Critical Reviews in Oncology/Hematology</i> , 2009 , 72, 10-20	7	46

237	Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: The French national Mortality 2005 study. <i>Journal of Hepatology</i> , 2009 , 50, 736-45	13.4	87
236	Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach. <i>Retrovirology</i> , 2009 , 6, 49	3.6	94
235	Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. <i>Lancet Oncology</i> , 2009 , 10, 1152-9	21.7	416
234	Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. <i>Lancet</i> , 2009 , 373, 1352-63	4.0	580
233	Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. <i>Aids</i> , 2009 , 23, 817-24	3.5	193
232	Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIV. <i>Aids</i> , 2009 , 23, 1163-9	3.5	125
231	Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. <i>Aids</i> , 2009 , 23, 2199-208	3.5	33
230	Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009 , 52, 357-63	3.1	24
229	Trends in post-infection CD4 cell counts and plasma HIV-1 RNA levels in HIV-1-infected patients in France between 1997 and 2005. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009 , 52, 422-6	3.1	13
228	Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study. <i>Antiviral Therapy</i> , 2009 , 14, 1065-74	1.6	74
227	Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. <i>Aids</i> , 2009 , 23, 2029-37	3.5	54
226	Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. <i>Aids</i> , 2009 , 23, 1743-53	3.5	175
225	Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France. <i>Aids</i> , 2009 , 23, 717-24	3.5	66
224	Rôle de l'enveloppe GP 41 dans la préparation d'un candidat vaccin contre le VIH. <i>Bulletin De L'Académie Nationale De Médecine</i> , 2009 , 193, 127-138	0.1	
223	CD4+ T-cell percentage is an independent predictor of clinical progression in AIDS-free antiretroviral-naïve patients with CD4+ T-cell counts >200 cells/mm ³ . <i>Antiviral Therapy</i> , 2009 , 14, 451-7	1.6	9
222	CD4+ T-cell percentage is an independent predictor of clinical progression in AIDS-free antiretroviral-naïve patients with CD4+ T-cell counts >200 cells/mm ³ . <i>Antiviral Therapy</i> , 2009 , 14, 451-457	1.6	22
221	Nevirapine-associated toxicity in Niger. <i>HIV Medicine</i> , 2008 , 9, 62-3	2.7	3
220	Initiatives for developing and comparing genotype interpretation systems: external validation of existing rule-based interpretation systems for abacavir against virological response. <i>HIV Medicine</i> , 2008 , 9, 27-40	2.7	5

219	Causes of the first AIDS-defining illness and subsequent survival before and after the advent of combined antiretroviral therapy. <i>HIV Medicine</i> , 2008 , 9, 246-56	2.7	47
218	Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor-sparing therapy in patients with lipoatrophy: results from the 96-week randomized ANRS 108 NoNuke Trial. <i>HIV Medicine</i> , 2008 , 9, 625-35	2.7	19
217	Surgical management of cervical intraepithelial neoplasia in HIV-infected women. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2008 , 141, 153-7	2.4	19
216	Maintaining antiretroviral therapy reduces the risk of AIDS-defining events in patients with uncontrolled viral replication and profound immunodeficiency. <i>Clinical Infectious Diseases</i> , 2008 , 46, 296-304	11.6	51
215	Characteristics of the env genes of HIV type 1 quasispecies in long-term nonprogressors with broadly neutralizing antibodies. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008 , 47, 274-84	3.1	17
214	Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. <i>Aids</i> , 2008 , 22, 1203-11	3.5	204
213	Imported malaria in HIV-infected patients enrolled in the ANRS CO4 FHDH study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008 , 49, 55-60	3.1	20
212	AIDS-related malignancies: state of the art and therapeutic challenges. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4834-42	2.2	92
211	Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 62, 797-808	5.1	22
210	Transcutaneous anti-influenza vaccination promotes both CD4 and CD8 T cell immune responses in humans. <i>Journal of Immunology</i> , 2008 , 180, 1482-9	5.3	92
209	HIV-1-infected patients from the French National Observatory experiencing virological failure while receiving enfuvirtide. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 62, 451-5	5.1	5
208	Initiatives for developing and comparing genotype interpretation systems: external validation of existing systems for didanosine against virological response. <i>Journal of Infectious Diseases</i> , 2008 , 198, 470-80	7	11
207	Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 61, 1362-8	5.1	11
206	Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. <i>Aids</i> , 2008 , 22, 1125-9	3.5	117
205	One or two enzyme-linked immunosorbent assay tests on the first serum sample for initial diagnosis of HIV-1 infection?. <i>Aids</i> , 2008 , 22, 2042-4	3.5	2
204	Increased cardiovascular risk in HIV infection: drugs, virus and immunity. <i>Aids</i> , 2008 , 22, 1625-7	3.5	11
203	Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452). <i>Aids</i> , 2008 , 22, 1313-22	3.5	70
202	Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?. <i>Aids</i> , 2008 , 22, 2481-92	3.5	16

201	Changes in causes of death among adults infected by HIV between 2000 and 2005: The "Mortalit ^e 2000 and 2005" surveys (ANRS EN19 and Mortavic). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008 , 48, 590-8	3.1	260
200	Dual nucleoside reverse transcriptase inhibitor therapy in the combination antiretroviral therapy era and predictors of discontinuation or switch to combination antiretroviral therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008 , 47, 206-11	3.1	1
199	Influence of control selection in nested case-control studies: the example of exposure to antiretroviral treatment (ART) and the risk of myocardial infarction (MI) in the French Hospital Database on HIV (FHDH-ANRS CO4). <i>Pharmacoepidemiology and Drug Safety</i> , 2008 , 17, 468-74	2.6	0
198	National survey of the prevalence and conditions of selection of HIV-1 reverse transcriptase K70E mutation. <i>Journal of Medical Virology</i> , 2008 , 80, 762-5	19.7	6
197	Clinical progression rates by CD4 cell category before and after the initiation of combination antiretroviral therapy (cART). <i>Open AIDS Journal</i> , 2008 , 2, 3-9	0.6	13
196	Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113). <i>Antiviral Therapy</i> , 2008 , 13, 67-76	1.6	31
195	Effect of Pioglitazone on HIV-1-Related Lipodystrophy: A Randomized Double-Blind Placebo-Controlled Trial (ANRS 113). <i>Antiviral Therapy</i> , 2008 , 13, 67-76	1.6	52
194	Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients. <i>Journal of Infection</i> , 2007 , 54, 367-74	18.9	46
193	BSE risk assessment as a basis for updating French screening policy. <i>Risk Analysis</i> , 2007 , 27, 1131-40	3.9	3
192	Complementary approach of data analysis and modeling to estimate the pattern of the BSE epidemic: the example of France. <i>Risk Analysis</i> , 2007 , 27, 1141-50	3.9	6
191	HIV-associated <i>Isospora belli</i> infection: incidence and risk factors in the French Hospital Database on HIV. <i>HIV Medicine</i> , 2007 , 8, 124-30	2.7	19
190	Wild type and H43Y variant of human TRIM5alpha show similar anti-human immunodeficiency virus type 1 activity both in vivo and in vitro. <i>Immunogenetics</i> , 2007 , 59, 511-5	3.2	23
189	Do tests devised to detect recent HIV-1 infection provide reliable estimates of incidence in Africa?. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007 , 45, 115-22	3.1	51
188	Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. <i>Journal of Experimental Medicine</i> , 2007 , 204, 2473-85	16.6	560
187	Serious psychiatric outcome of subjects prenatally exposed to diethylstilboestrol in the E3N cohort study. <i>Psychological Medicine</i> , 2007 , 37, 1315-22	6.9	11
186	Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir. <i>Clinical Infectious Diseases</i> , 2007 , 44, 120-7	11.6	4
185	Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. <i>Aids</i> , 2007 , 21, 1185-97	3.5	218
184	HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART. <i>Aids</i> , 2007 , 21, 2243-5	3.5	27

183	Observation versus intervention in the evaluation of drugs: the story of hormone replacement therapy. <i>Comptes Rendus - Biologies</i> , 2007 , 330, 347-55	1.4	2
182	Estimating incidence of the French BSE infection using a joint analysis of both asymptomatic and clinical BSE surveillance data. <i>Mathematical Biosciences</i> , 2007 , 209, 90-107	3.9	7
181	Prevalence of HIV-1 drug resistance in treated patients: a French nationwide study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007 , 46, 12-8	3.1	47
180	Frequency, determinants and consequences of delayed access to care for HIV infection in France. <i>Antiviral Therapy</i> , 2007 , 12, 89-96	1.6	82
179	First-line highly active antiretroviral regimens in 2001-2002 in the French Hospital Database on HIV: combination prescribed and biological outcomes. <i>Antiviral Therapy</i> , 2007 , 12, 317-24	1.6	5
178	First-line Highly Active Antiretroviral Regimens in 2001-2002 in the French Hospital Database on HIV: Combination Prescribed and Biological Outcomes. <i>Antiviral Therapy</i> , 2007 , 12, 317-324	1.6	9
177	A 6-Month Interruption of Antiretroviral Therapy Improves Adipose Tissue Function in HIV-Infected Patients: The ANRS EP29 Lipostop Study. <i>Antiviral Therapy</i> , 2007 , 12, 1273-1284	1.6	27
176	Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performance. <i>Journal of Medical Virology</i> , 2006 , 78, 153-60	19.7	53
175	Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir. <i>Aids</i> , 2006 , 20, 2099-106	3.5	9
174	HIV infection in older patients in the HAART era. <i>Journal of Antimicrobial Chemotherapy</i> , 2006 , 57, 4-7	5.1	105
173	Rates of disease progression according to initial highly active antiretroviral therapy regimen: a collaborative analysis of 12 prospective cohort studies. <i>Journal of Infectious Diseases</i> , 2006 , 194, 612-22	7	37
172	Differential impact of combination antiretroviral therapy in preventing Kaposi's sarcoma with and without visceral involvement. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3408-14	2.2	46
171	Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 2006 , 24, 4123-8	2.2	174
170	HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. <i>Lancet, The</i> , 2006 , 368, 451-8	4.0	187
169	Effects of type of smoking (pipe, cigars or cigarettes) on biological indices of tobacco exposure and toxicity. <i>Lung Cancer</i> , 2006 , 54, 11-8	5.9	37
168	How was the French BSE epidemic underestimated?. <i>Comptes Rendus - Biologies</i> , 2006 , 329, 106-16	1.4	9
167	Predictors identified for losses to follow-up among HIV-seropositive patients. <i>Journal of Clinical Epidemiology</i> , 2006 , 59, 829-835	5.7	77
166	Number of deaths among HIV-infected adults in France in 2000, three-source capture-recapture estimation. <i>Epidemiology and Infection</i> , 2006 , 134, 1345-52	4.3	23

165	Specific adaptive humoral response against a gp41 motif inhibits CD4 T-cell sensitivity to NK lysis during HIV-1 infection. <i>Aids</i> , 2006 , 20, 1795-804	3.5	30
164	Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity. <i>Aids</i> , 2006 , 20, 1923-30	3.5	56
163	Risk factors for osteonecrosis in HIV-infected patients: impact of treatment with combination antiretroviral therapy. <i>Aids</i> , 2006 , 20, 1627-35	3.5	41
162	Yearly number of patients diagnosed with primary HIV-1 infection in France estimated by a capture-recapture approach. <i>Aids</i> , 2006 , 20, 2392-5	3.5	9
161	On the comparison of artificial network and interpretation systems based on genotype resistance mutations in HIV-1-infected patients. <i>Aids</i> , 2006 , 20, 2118-20	3.5	
160	The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006 , 41, 352-60	3.1	84
159	Influence of gender and HIV transmission group on initial highly active antiretroviral therapy prescription and treatment response. <i>HIV Medicine</i> , 2006 , 7, 520-9	2.7	27
158	Comparison of dynamic treatment regimes via inverse probability weighting. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2006 , 98, 237-42	3.1	168
157	Including pre-AIDS mortality in back-calculation model to estimate HIV prevalence in France, 2000. <i>European Journal of Epidemiology</i> , 2006 , 21, 389-96	12.1	4
156	Lamivudine and Indinavir/Ritonavir Maintenance Therapy in Highly Pretreated HIV-Infected Patients (Vista Anrs 109). <i>Antiviral Therapy</i> , 2006 , 11, 889-900	1.6	3
155	Limited Impact of Immunosuppression and Haart on the Incidence of Cervical Squamous Intraepithelial Lesions in HIV-Positive Women. <i>Antiviral Therapy</i> , 2006 , 11, 1091-1096	1.6	12
154	Evaluation of a peer support group therapy for HIV-infected adolescents. <i>Aids</i> , 2005 , 19, 1501-8	3.5	92
153	Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication. <i>Aids</i> , 2005 , 19, 25-33	3.5	43
152	Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. <i>Journal of Hepatology</i> , 2005 , 42, 799-805	13.4	252
151	Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094). <i>Vaccine</i> , 2005 , 23, 4292-301	4.1	42
150	Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. <i>International Journal of Epidemiology</i> , 2005 , 34, 121-30	7.8	261
149	High rate of recurrence of cervical intraepithelial neoplasia after surgery in HIV-positive women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005 , 39, 412-8	3.1	47
148	Response to highly active antiretroviral therapy at 6 months and long-term disease progression in HIV-1 infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005 , 39, 284-92	3.1	26

147	No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients. <i>Aids</i> , 2005 , 19, 1643-7	3.5	36
146	French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naïve chronically infected patients in 2001-2002. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005 , 38, 545-52	3.1	99
145	Alterations of self-reactive antibody repertoires in HIV disease: an insight into the role of T cells in the selection of autoreactive B cells. <i>Immunology Letters</i> , 2005 , 99, 198-208	4.1	19
144	Prevalence of complete resistance to at least two classes of antiretroviral drugs in treated HIV-1-infected patients: a French nationwide study. <i>Journal of Medical Virology</i> , 2005 , 76, 441-6	19.7	10
143	Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097). <i>Journal of Medical Virology</i> , 2005 , 77, 345-50	19.7	24
142	Opportunistic infections as causes of death in HIV-infected patients in the HAART era in France. <i>Scandinavian Journal of Infectious Diseases</i> , 2005 , 37, 482-7		52
141	Combination of HIV-1-specific CD4 Th1 cell responses and IgG2 antibodies is the best predictor for persistence of long-term nonprogression. <i>Journal of Infectious Diseases</i> , 2005 , 191, 2053-63	7	107
140	Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. <i>Journal of Infectious Diseases</i> , 2005 , 192, 958-66	7	356
139	Development and validation of an immunoassay for identification of recent human immunodeficiency virus type 1 infections and its use on dried serum spots. <i>Journal of Clinical Microbiology</i> , 2005 , 43, 4441-7	9.7	82
138	Repertoire, diversity, and differentiation of specific CD8 T cells are associated with immune protection against human cytomegalovirus disease. <i>Journal of Experimental Medicine</i> , 2005 , 201, 1999-2010	16.6	97
137	Impact of newly available drugs on clinical progression in patients with virological failure after exposure to three classes of antiretrovirals. <i>Antiviral Therapy</i> , 2005 , 10, 563-73	1.6	3
136	Impact of Newly Available Drugs on Clinical Progression in Patients with Virological Failure after Exposure to Three Classes of Antiretrovirals. <i>Antiviral Therapy</i> , 2005 , 10, 563-573	1.6	8
135	Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2004 , 48, 644-7	5.9	16
134	Nucleoside analogue use before and during highly active antiretroviral therapy and virus load rebound. <i>Journal of Infectious Diseases</i> , 2004 , 190, 675-87	7	4
133	Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2004 , 48, 4687-92	5.9	43
132	Contraceptive use in HIV-positive women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004 , 36, 714-20	3.1	21
131	GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy. <i>HIV Medicine</i> , 2004 , 5, 352-9	2.7	56
130	Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. <i>Cancer</i> , 2004 , 101, 317-24	6.4	186

129	Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients. <i>Journal of Medical Virology</i> , 2004 , 74, 16-20	19.7	19
128	Evaluating therapeutic vaccines in patients infected with HIV. <i>Expert Review of Vaccines</i> , 2004 , 3, S169-77.2	5.2	11
127	Comparing the public health burden of chronic hepatitis C and HIV infection in France. <i>Journal of Hepatology</i> , 2004 , 40, 319-26	13.4	51
126	Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097). <i>Aids</i> , 2004 , 18, 217-26	3.5	64
125	Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV. <i>Aids</i> , 2004 , 18, 2029-38	3.5	145
124	The unrecognised French BSE epidemic. <i>Veterinary Research</i> , 2004 , 35, 349-62	3.8	33
123	Genotypic Determinants of the Virological Response to Tenofovir Disoproxil Fumarate in Nucleoside Reverse Transcriptase Inhibitor-Experienced Patients. <i>Antiviral Therapy</i> , 2004 , 9, 315-323	1.6	20
122	Impact of Insertions in the HIV-1 P6 Ptapp Region on the Virological Response to Amprenavir. <i>Antiviral Therapy</i> , 2004 , 9, 221-227	1.6	11
121	Clinically Validated Genotype Analysis: Guiding Principles and Statistical Concerns. <i>Antiviral Therapy</i> , 2004 , 9, 465-478	1.6	40
120	No influence of human herpesvirus 8 infection on the progression of HIV-1 infection in initially asymptomatic patients. <i>Aids</i> , 2003 , 17, 1394-6	3.5	5
119	Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. <i>Aids</i> , 2003 , 17, 2479-86	3.5	392
118	Modeling the time course of CD4 T-lymphocyte counts according to the level of virologic rebound in HIV-1-infected patients on highly active antiretroviral therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003 , 34, 50-7	3.1	16
117	Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France. <i>Aids</i> , 2003 , 17, 2635-43	3.5	86
116	Poly-lactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. <i>Aids</i> , 2003 , 17, 2471-7	3.5	249
115	IL-2 therapy and thymic production of naive CD4 T cells in HIV-infected patients with severe CD4 lymphopenia. <i>Aids</i> , 2003 , 17, 841-50	3.5	21
114	Clinically relevant interpretation of genotype for resistance to abacavir. <i>Aids</i> , 2003 , 17, 1795-802	3.5	49
113	Quantitation of cytomegalovirus (CMV) DNA by real-time PCR for occurrence of CMV disease in HIV-infected patients receiving highly active antiretroviral therapy. <i>Journal of Medical Virology</i> , 2003 , 69, 401-7	19.7	12
112	Markov modelling of changes in HIV-specific cytotoxic T-lymphocyte responses with time in untreated HIV-1 infected patients. <i>Statistics in Medicine</i> , 2003 , 22, 1675-90	2.3	13

111	Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. <i>Lancet, The</i> , 2003 , 362, 679-86	4.0	212
110	Clinical and immunologic outcome in patients with human immunodeficiency virus infection, according to virologic efficacy in the year after virus undetectability, during antiretroviral therapy. <i>Clinical Infectious Diseases</i> , 2003 , 37, 1517-26	11.6	20
109	Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. <i>Journal of Clinical Oncology</i> , 2003 , 21, 3447-53	2.2	285
108	Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2003 , 47, 594-600	5.9	88
107	Bivariate longitudinal model for the analysis of the evolution of HIV RNA and CD4 cell count in HIV infection taking into account left censoring of HIV RNA measures. <i>Journal of Biopharmaceutical Statistics</i> , 2003 , 13, 271-82	1.3	17
106	Quantitative markers for cytomegalovirus disease in HIV-infected patients receiving highly active antiretroviral therapy. <i>Aids</i> , 2003 , 17, 784-6	3.5	1
105	Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088). <i>Antiviral Therapy</i> , 2003 , 8, 427-34	1.6	13
104	Increase of HIV-1 Pro-Viral Dna per Million Peripheral Blood Mononuclear Cells in Patients with Advanced HIV Disease (Cd4<200 Cells/Mm3) Receiving Interleukin 2 Combined with Haart Versus Haart Alone (Anrs-082 Trial). <i>Antiviral Therapy</i> , 2003 , 8, 233-237	1.6	6
103	Predictors of the Virological Response to a Change in the Antiretroviral Treatment Regimen in HIV-1-Infected Patients Enrolled in a Randomized Trial Comparing Genotyping, Phenotyping and Standard of Care (Narval Trial, Anrs 088). <i>Antiviral Therapy</i> , 2003 , 8, 427-434	1.6	30
102	Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort. <i>British Journal of Haematology</i> , 2002 , 116, 383-389	4.5	7
101	Interleukin 2 treatment does not modify hepatitis B or C replication in human immunodeficiency virus-infected patients: results from a randomized control trial. <i>Hepatology</i> , 2002 , 35, 238-9	11.2	7
100	The incubation period of kuru. <i>Epidemiology</i> , 2002 , 13, 402-8	3.1	29
99	Semen alterations in HIV-1 infected men. <i>Human Reproduction</i> , 2002 , 17, 2112-8	5.7	90
98	Impact of highly active antiretroviral therapy on the incidence of visceral leishmaniasis in a French cohort of patients infected with human immunodeficiency virus. <i>Journal of Infectious Diseases</i> , 2002 , 186, 1366-70	7	64
97	Correlation between breadth of memory HIV-specific cytotoxic T cells, viral load and disease progression in HIV infection. <i>Aids</i> , 2002 , 16, 2399-407	3.5	64
96	Interleukin-2 accelerates CD4 cell reconstitution in HIV-infected patients with severe immunosuppression despite highly active antiretroviral therapy: the ILSTIM study--ANRS 082. <i>Aids</i> , 2002 , 16, 2027-34	3.5	58
95	Time to AIDS from 1992 to 1999 in HIV-1-infected subjects with known date of infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002 , 30, 81-7	3.1	24
94	Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. <i>Aids</i> , 2002 , 16, 727-36	3.5	161

93	Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. <i>Lancet, The</i> , 2002 , 360, 119-29	4.0	1246
92	Decrease in HIV-1 seminal shedding in men receiving highly active antiretroviral therapy: an 18 month longitudinal study (ANRS EP012). <i>Aids</i> , 2002 , 16, 486-8	3.5	48
91	Time to AIDS From 1992 to 1999 in HIV-1 Infected Subjects With Known Date of Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002 , 30, 81-87	3.1	10
90	Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial. <i>Antiviral Therapy</i> , 2002 , 7, 211-8	1.6	10
89	Impact of Stavudine Phenotype and Thymidine Analogues Mutations on Viral Response to Stavudine plus Lamivudine in Altis 2 Anrs Trial. <i>Antiviral Therapy</i> , 2002 , 7, 211-218	1.6	15
88	Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. <i>Blood</i> , 2001 , 98, 2339-44	2.2	304
87	Primary Prevention With Cotrimoxazole for HIV-1 Infected Adults: Results of the Pilot Study in Dakar, Senegal. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001 , 26, 130-136	3.1	21
86	Pneumocystis carinii Pneumonia Recurrence in HIV Patients on Highly Active Antiretroviral Therapy: Secondary Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001 , 26, 151-158	3.1	10
85	Impact of early-untreated HIV infection on chronic hepatitis C in intravenous drug users: a case-control study. <i>Aids</i> , 2001 , 15, 2011-6	3.5	26
84	HIV Incidence Estimates Among Women of Childbearing Age in the Area Around Paris, France: No Evidence for Any Effect of Age or Time. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001 , 27, 492-498	3.1	
83	Including polymerase chain reaction in screening for hepatitis C virus RNA in blood donations is not cost-effective. <i>Vox Sanguinis</i> , 2001 , 80, 199-204	3.1	20
82	Prevalence of resistance mutations in antiretroviral-naïve chronically HIV-infected patients in 1998: a French nationwide study. <i>Aids</i> , 2001 , 15, 1777-82	3.5	31
81	Pneumocystis carinii pneumonia recurrence in HIV patients on highly active antiretroviral therapy: secondary prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001 , 26, 151-8	3.1	6
80	HIV type 1-specific IgG2 antibodies: markers of helper T cell type 1 response and prognostic marker of long-term nonprogression. <i>AIDS Research and Human Retroviruses</i> , 2001 , 17, 1435-46	1.6	74
79	Incidence and risk factors for toxoplasmic encephalitis in human immunodeficiency virus-infected patients before and during the highly active antiretroviral therapy era. <i>Clinical Infectious Diseases</i> , 2001 , 33, 1747-55	11.6	102
78	L'introduction de la PCR dans le dépistage du virus de l'hépatite C dans les dons de sang : du mésusage du principe de précaution.. <i>Medecine/Sciences</i> , 2001 , 17, 344		4
77	The French haemophilia cohort: rationale and organization of a long-term national pharmacosurveillance system. <i>Haemophilia</i> , 2001 , 7, 82-8	3.3	13
76	'Do HIV-infected injecting drug users over-report adherence to highly active antiretroviral therapy?' A comparison between patients' self-reports and serum protease inhibitor concentrations in the French Manif 2000 cohort study. <i>Aids</i> , 2001 , 15, 1075-7	3.5	28

75	Low-Rate Emergence of Thymidine Analogue Mutations and Multi-Drug Resistance Mutations in the HIV-1 Reverse Transcriptase Gene in Therapy-Naive Patients Receiving Stavudine plus Lamivudine Combination Therapy. <i>Antiviral Therapy</i> , 2001 , 6, 179-183	1.6	18
74	Didanosine Dosed Once Daily Is Equivalent to Twice Daily Dosing for Patients on Double or Triple Combination Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2000 , 24, 418-424	3.1	2
73	Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy. <i>Aids</i> , 2000 , 14, 1041-9	3.5	54
72	Induction and maintenance therapy of cytomegalovirus central nervous system infection in HIV-infected patients. <i>Aids</i> , 2000 , 14, 517-24	3.5	81
71	Factors predictive of disease progression and death in AIDS-related Kaposi's sarcoma. <i>HIV Medicine</i> , 2000 , 1, 232-7	2.7	8
70	Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor. <i>Aids</i> , 2000 , 14, 141-9	3.5	142
69	Record-linkage between two anonymous databases for a capture-recapture estimation of underreporting of AIDS cases: France 1990-1993. The Clinical Epidemiology Group from Centres d'Information et de Soins de l'Immunodficiency Humaine. <i>International Journal of Epidemiology</i> , 2000 , 29, 168-74	7.8	30
68	Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. <i>Annals of Internal Medicine</i> , 2000 , 133, 401-10	8	284
67	Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1. <i>Science</i> , 2000 , 287, 2274-7	33.3	280
66	Combined Genotypes of CCR5, CCR2, SDF1, and HLA Genes Can Predict the Long-Term Nonprogressor Status in Human Immunodeficiency Virus-1Infected Individuals. <i>Blood</i> , 1999 , 93, 936-941	2.2	193
65	Survival improvement of AIDS-related progressive multifocal leukoencephalopathy in the era of protease inhibitors. Clinical Epidemiology Group. French Hospital Database on HIV. <i>Aids</i> , 1999 , 13, 1881-7	3.5	73
64	Direct HIV testing in blood donations: variation of the yield with detection threshold and pool size. <i>Transfusion</i> , 1999 , 39, 1141-4	2.9	22
63	Risk-benefit analysis of nucleic acid testing: the French experience. <i>Biologicals</i> , 1999 , 27, 343-8	1.8	5
62	Timing of human immunodeficiency virus type 1 (HIV-1) transmission from mother to child: bayesian estimation using a mixture. <i>Statistics in Medicine</i> , 1999 , 18, 815-33	2.3	22
61	Is the AIDS incubation time changing? A back-calculation approach. <i>Statistics in Medicine</i> , 1999 , 18, 1031-43	4.3	4
60	Visit-driven endpoints in randomized HIV/AIDS clinical trials: impact of missing data on treatment difference measured on summary statistics. <i>Statistics in Medicine</i> , 1999 , 18, 1803-17; discussion 1819	2.3	9
59	Status of long-term asymptomatic HIV-1 infection correlates with viral load but not with virus replication properties and cell tropism. <i>Journal of Medical Virology</i> , 1999 , 58, 256-263	19.7	69
58	Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study Groups. <i>Aids</i> , 1999 , 13, 2075-82	3.5	106

57	Decreased peripheral circulation of HIV-infected cells in a subset of long-term nonprogressors. The French ALT Study Group. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 1999 , 21, 253-5	3.1	3
56	Incubation period of Creutzfeldt-Jakob disease in human growth hormone recipients in France. <i>Neurology</i> , 1999 , 53, 1197-201	6.5	55
55	Combined Genotypes of CCR5, CCR2, SDF1, and HLA Genes Can Predict the Long-Term Nonprogressor Status in Human Immunodeficiency Virus-1 Infected Individuals. <i>Blood</i> , 1999 , 93, 936-941	2.2	3
54	Impact of opportunistic diseases on survival in HIV-infected patients in France, 1992-1997. Clinical Epidemiology Group from Centres d'Information et de Soins de l'Immunodficiency Humaine. <i>Aids</i> , 1999 , 13, 1789-90	3.5	
53	Status of long-term asymptomatic HIV-1 infection correlates with viral load but not with virus replication properties and cell tropism 1999 , 58, 256		1
52	Pneumocystis and pneumocystosis in Europe at the end of the 20th century. <i>FEMS Immunology and Medical Microbiology</i> , 1998 , 22, 87-91		6
51	Usefulness of pulmonary regurgitation Doppler tracings in predicting in-hospital and long-term outcome in patients with inferior wall acute myocardial infarction. <i>American Journal of Cardiology</i> , 1998 , 81, 276-81	3	12
50	Lack of association between human leukocyte antigens and the anti-Hu syndrome in patients with small-cell lung cancer. <i>Neurology</i> , 1998 , 50, 565-6	6.5	10
49	Apparent enhancement of perinatal transmission of human immunodeficiency virus type 1 by high maternal anti-gp160 antibody titer. <i>Journal of Infectious Diseases</i> , 1998 , 177, 1737-41	7	27
48	Serum ferritin, desferrioxamine, and evolution of HIV-1 infection in thalassemic patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1998 , 18, 473-8		46
47	Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy. <i>Aids</i> , 1998 , 12, 1459-64	3.5	147
46	Efficacy and tolerability of stavudine plus lamivudine in treatment-naive and treatment-experienced patients with HIV-1 infection. <i>Annals of Internal Medicine</i> , 1998 , 129, 525-31	8	36
45	Decreased prevalence of intestinal cryptosporidiosis in HIV-infected patients concomitant to the widespread use of protease inhibitors. <i>Aids</i> , 1998 , 12, 1395-7	3.5	27
44	Effect of interferon alpha on high serum androgen concentrations in HIV positive men with Kaposi's sarcoma. <i>Journal of Clinical Pathology</i> , 1997 , 50, 341-5	3.9	3
43	Timing of mother-to-child HIV-1 transmission and diagnosis of infection based on polymerase chain reaction in the neonatal period by a non-parametric method. <i>Aids</i> , 1997 , 11, 1183-4	3.5	36
42	Patterns of disclosure and perceptions of the human immunodeficiency virus in infected elementary school-age children. <i>JAMA Pediatrics</i> , 1997 , 151, 978-85		60
41	Long-term nonprogression in HIV infection. Clinical Epidemiology Group from the Centre d'Information et de Soins de l'Immunodficiency Humaine. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1997 , 16, 409-11		6
40	Zidovudine in patients with HIV infection. <i>Annals of Internal Medicine</i> , 1996 , 124, 372; author reply 372-38		3

39	Estimation of the size of the HIV/AIDS epidemic due to blood transfusion in France. <i>International Journal of Epidemiology</i> , 1995 , 24, 441-5	7.8	4
38	Differences in androgens of HIV positive patients with and without Kaposi sarcoma. <i>Journal of Clinical Pathology</i> , 1995 , 48, 513-8	3.9	14
37	Can antiviral agents decrease the occurrence of Kaposi's sarcoma? Clinical Epidemiology Group from Centres d'Information et de Soins de l'Immunodficiency Humaine. <i>Lancet, The</i> , 1995 , 346, 578	4.0	22
36	A prospective evaluation of clinical criteria and polymerase chain reaction assay of cerebrospinal fluid for the diagnosis of cytomegalovirus-related neurological diseases during AIDS. <i>Aids</i> , 1995 , 9, 253-260	3.5	36
35	Estimated timing of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission by use of a Markov model. The HIV Infection in Newborns French Collaborative Study Group. <i>American Journal of Epidemiology</i> , 1995 , 142, 1330-7	3.8	201
34	Hemodynamic criteria for diagnosis of right ventricular ischemia associated with inferior wall left ventricular acute myocardial infarction. <i>American Journal of Cardiology</i> , 1995 , 76, 220-5	3	9
33	Relations between Doppler tracings of pulmonary regurgitation and invasive hemodynamics in acute right ventricular infarction complicating inferior wall left ventricular infarction. <i>American Journal of Cardiology</i> , 1995 , 75, 425-30	3	13
32	How much would the safety of blood transfusion be improved by including p24 antigen in the battery of tests?. <i>Transfusion</i> , 1995 , 35, 542-7	2.9	10
31	When is the epidemic warning cut-off point exceeded?. <i>European Journal of Epidemiology</i> , 1994 , 10, 475-62.1	6.1	15
30	Epidemiologic comparison of human T-lymphotropic virus type I-infected blood donors from endemic and nonendemic regions over a 3-year period. <i>Transfusion</i> , 1994 , 34, 198-201	2.9	4
29	Dose of desferrioxamine and evolution of HIV-1 infection in thalassaemic patients. <i>British Journal of Haematology</i> , 1994 , 87, 849-52	4.5	42
28	Reproducibility of non-invasive measurement and of short-term variability of blood pressure and heart rate in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 1994 , 38, 109-15	3.8	17
27	Randomized study of two doses of didanosine in children infected with human immunodeficiency virus. <i>Journal of Pediatrics</i> , 1993 , 122, 966-73	3.6	11
26	Cumulative incidence of HIV infection and AIDS case prediction in France. <i>Lancet, The</i> , 1993 , 342, 436-7	4.0	5
25	Progression to AIDS in French haemophiliacs: association with HLA-B35. <i>Aids</i> , 1993 , 7, 497-500	3.5	46
24	Timing of mother-to-child HIV-1 transmission depends on maternal status. The HIV Infection in Newborns French Collaborative Study Group. <i>Aids</i> , 1993 , 7 Suppl 2, S49-52	3.5	44
23	A new approach to estimating AIDS incubation times: results in homosexual infected men. <i>Journal of Epidemiology and Community Health</i> , 1992 , 46, 582-6	5.1	11
22	Trends in zidovudine prescription since 1987 in AIDS-free HIV-positive French patients attending university hospitals. <i>Aids</i> , 1992 , 6, 1405-6	3.5	3

21	Towards a new predictor of AIDS progression through the quantitation of HIV-1 DNA copies by PCR in HIV-infected individuals. <i>British Journal of Haematology</i> , 1992 , 82, 467-71	4.5	15
20	Incidence of AIDS in HIV-1 infected thalassaemia patients. European and Mediterranean W.H.O. Working Group on Haemoglobinopathies and CooleyCare. <i>British Journal of Haematology</i> , 1992 , 81, 109-125	4.5	8
19	A routine tool for detection and assessment of epidemics of influenza-like syndromes in France. <i>American Journal of Public Health</i> , 1991 , 81, 97-9	5.1	103
18	Initiation of insulin treatment after 70 years of age: patient status 2 years later. <i>Diabetic Medicine</i> , 1991 , 8, 773-7	3.5	21
17	A rational attitude toward serum alanine aminotransferase measurement by blood banks, based on a longitudinal study of a cohort of repeat blood donors. <i>Transfusion</i> , 1991 , 31, 201-4	2.9	1
16	Epstein-Barr virus transactivator antibodies in HIV infection. <i>Lancet, The</i> , 1991 , 338, 574	4.0	4
15	The prevalence of diabetes mellitus in the adult population of Guadeloupe as estimated by history or fasting hyperglycemia. <i>Diabetes Research and Clinical Practice</i> , 1991 , 12, 209-16	7.4	16
14	SMBG in NIDDM patients treated by general practitioners in France. <i>Diabetes Care</i> , 1990 , 13, 454	14.6	
13	Anti-HBc Testing Can Decrease the Residual Risk of Transfusion-Related HIV Transmission by More Than One Third. <i>Vox Sanguinis</i> , 1990 , 59, 248-250	3.1	5
12	What is known about the prevention of congenital toxoplasmosis?. <i>Lancet, The</i> , 1990 , 336, 359-61	4.0	57
11	Incubation time for AIDS from French transfusion-associated cases. <i>Nature</i> , 1989 , 338, 768-9	50.4	20
10	Cell cycle models and mother-daughter correlation. <i>Journal of Theoretical Biology</i> , 1988 , 131, 255-62	2.3	15
9	The cost of diabetes in France. <i>Health Policy</i> , 1988 , 9, 39-48	3.2	16
8	Epidemiology of toxoplasmosis among pregnant women in the Paris area. <i>International Journal of Epidemiology</i> , 1988 , 17, 595-602	7.8	74
7	Incubation time for AIDS. <i>Nature</i> , 1987 , 328, 582	50.4	4
6	Bedside estimation of microalbuminuria. <i>Lancet, The</i> , 1986 , 1, 268-9	4.0	1
5	Rotation of the cell nucleus in living cells: a quantitative analysis. <i>Biology of the Cell</i> , 1985 , 54, 135-42	3.5	25
4	Lifelong variations in heart rates in SPF Sprague Dawley rats of both sexes. Statistical correlations with body weights. <i>Pflugers Archiv European Journal of Physiology</i> , 1979 , 380, 189-95	4.6	9

3 Modeling remdesivir antiviral efficacy in COVID-19 hospitalized patients of the randomized, controlled, open-label DisCoVeRy trial 1

2 HIV-related neoplasms797-808

1 HIV-Related Neoplasms797-808